

Integrum updates financial calendar following change of financial year

Mölnadal, Sweden, October 15, 2026 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces an updated financial calendar following the company's transition to a calendar year as its financial year.

The current financial year will end on December 31, 2026, meaning that the final reporting period, November–December 2026, will cover two months. From January 1, 2027, the company's financial reporting will follow the calendar year.

Updated financial calendar

Event	Date
Year-end report 2026 (November–December 2026)	February 11, 2027
Interim report Q1 2027	May 13, 2027
Annual General Meeting 2027	May 27, 2027
Half-year report Q2 2027	August 26, 2027
Interim report Q3 2027	November 11, 2027
Year-end report 2027	February 10, 2028

The updated financial calendar will also be published on the company's website, www.integrum.se.

For further information, please contact:

Louise Wåhlin, CFO

Tel: +46 734 63 73 03

Email: louise.wahlin@integrum.se

Certified Adviser

DNB Carnegie Investment Bank AB (publ)

+46 8-588 685 70

certifiedadviser@dnbcarnegie.se

About Us

Integrum is a Swedish medical technology company developing solutions to improve mobility and quality of life for people living with limb loss. The company's OPRA™ Implant System is based on osseointegration, whereby a prosthesis is anchored directly to the skeleton without the need for a conventional socket. The system has been used to treat more than 1,000 patients worldwide and is certified under the EU Medical Device Regulation (MDR) and approved by the U.S. Food and Drug Administration (FDA). In parallel, Integrum is developing next-generation bionic solutions focused on intuitive prosthetic control and sensory feedback.

Integrum AB is listed on Nasdaq First North Growth Market (INTEG B). Learn more at www.integrum.se.